HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)

Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Hangzhou Bioer Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hangzhou-bioer-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33513:1" rel="noopener">Hangzhou Bioer Technology (BIOER HK)</a>’s outstanding financial performance was mainly driven by the pandemic.</li>
<li>After the pandemic is under control,it depends on how many reagents in terminal scenarios are reported to have specified Bioer's PCR instruments, which could judge if Bioer’s performance is sustainable.</li>
<li>With just three reagents got approval, it remains to be seen whether Bioer would continue to rise or fall instead based on our analysis. </li>
</ul>



Hangzhou Bioer Technology (BIOER HK)’s outstanding financial performance was mainly driven by the pandemic.
After the pandemic is under control,it depends on how many reagents in terminal scenarios are reported to have specified Bioer's PCR instruments, which could judge if Bioer’s performance is sustainable.
With just three reagents got approval, it remains to be seen whether Bioer would continue to rise or fall instead based on our analysis. 


Pre-IPO Hangzhou Bioer Technology - Key Judgement on Performance Sustainability and Other Concerns